Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Dexamethasone 49Metformin 47Cyclophosphamide 42Saline Solution 38Cytarabine 34Sodium Chloride 32Bupivacaine 31Vincristine 27Cisplatin 26Propofol 25Methotrexate 25Letrozole 24Fluorouracil 24Dexmedetomidine 24Doxorubicin 23Fentanyl 22Carboplatin 22Etoposide 19Rituximab 18Morphine 18Bevacizumab 18Acetaminophen 18Lidocaine 17Granulocyte Colony-Stimulating Factor 17Prednisone 16Mercaptopurine 16Docetaxel 16Clomiphene 16Sevoflurane 15Ropivacaine 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × OTHER × flumatinib × Clear all
NCT05071482 2025-05-01

Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Terminated
39 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04677439 2022-03-16

Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure

Shenzhen Second People's Hospital

Phase 4 Unknown
200 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡